Overview

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

Status:
Active, not recruiting
Trial end date:
2021-07-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the long-term safety and tolerability of ABBV-8E12 in subjects with early AD.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie
Treatments:
Tilavonemab